Galderma is the only pure-play dermatology company with more than 40 years of heritage, and its significant presence at the 25th World Congress of Dermatology (WCD) underscores its leadership in this space. More details on Galderma’s scientific presentations at WCD can be found below.
First Author |
Abstract # and title |
Presentation type |
Prurigo nodularis |
||
S. Stander |
Patients with prurigo nodularis treated with nemolizumab achieved itch-free state: results from a phase 3 trial (OLYMPIA 2) |
Late-breaking presentation July 4, 2023 15:30 - 15:40, Level 3 - Room 330 |
SG. Kwatra |
Pruritus and clinical severity measures among patients with prurigo nodularis |
Oral presentation July 7, 2023 14:50 - 15:00 Level 3 - Room 327 |
D. Rodriguez |
Measurement of self-reported sleep disturbance in adults with prurigo nodularis |
e-poster |
SG. Kwatra |
The burden of disease for prurigo nodularis in a commercially and medicare-insured U.S. population: a retrospective, case-control study |
Oral presentation 14:40 - 14:50 Level 3 - Room 327 |
SG. Kwatra |
Sleep disorders in patients with prurigo nodularis: a population-level, matched-cohort study using The Health Improvement Network |
Oral presentation July 5, 2023 08:30 - 08:40, Level 3 - Room 327 |
Sensitive skin, dry skin, and healthy aging |
||
V. Le Noel |
A novel active complex reduces neuro-mediated cutaneous inflammation to optimize hydration of dry, dehydrated sensitive skin: clinical evidence |
e-poster |
C. Vaudour |
Clinical evaluation of dermo-cosmetics on five signs of skin sensitivity |
e-poster |
S. Anjuwon |
Sensiscale: a new tool to diagnose sensitive skin and monitor efficacy: Clinical evidence after topical targeted products (sensitive skin segmentation + products performance) |
e-poster |
N. Joly-Tonetti |
Daily care of sensitive skin targeting skin barrier, hydration and (neuro)-inflammation: in-vitro efficacy of a specific complex of ingredients |
e-poster |
G. Pellacani |
Sensitive skin: unexpected skin morphology and vascularization aspects in resting phase |
e-poster |
N. Joly-Tonetti |
A novel active complex for sensitive skin targeting pigmentation with anti-inflammatory activity |
e-poster |
Y. Zielinski |
Resilience - what does it mean in the context of sensitive skin? |
e-poster |
MH. Meckfessel |
A novel, 100% mineral liquid facial sunscreen SPF 50 is significantly preferred to a 100% mineral facial lotion SPF 50 |
e-poster |
C. Emesiani |
Heatmap evaluation of facial hydration |
e-poster |
P. Lio |
Efficacy, tolerability, and acceptability of a cream formulated with shea butter, vitamin E, and safflower seed oil in subjects with dry skin |
e-poster |
MH. Meckfessel |
A moisturizing cream with panthenol, glycerin, and niacinamide provides superior skin barrier recovery |
e-poster |
P. Lio |
A new healing ointment rapidly relieves and heals dry, cracked, calloused skin |
e-poster |
V. Le Noel |
Baby-specific cleansers, moisturizers, and diaper creams provide 5 folds of protection in clinical evaluation |
e-poster |
JW. Fluhr |
Glycerol combined with a natural sugar-derived complex modulate differentially stratum corneum water-binding properties and structural parameters in an in-vitro RAMAN-Spectroscopy desorption model |
e-poster |
N. Joly-Tonetti |
Tolerability and efficacy of a new healthy aging skin care strategy for sensitive skin |
e-poster |
G. Pellacani |
How to address healthy ageing in sensitive skin: an innovative tailored approach |
e-poster |
Onychomychosis |
||
N. Joly-Tonetti |
Quantification and visualization of amorolfine and terbinafine penetration profiles in onychomycosis-infected nails using MALDI-FTICR |
e-poster |
N. Joly-Tonetti |
Better penetration profile of the antifungal amorolfine than naftifine and tioconazole in onychomycosis-infected nails quantified by matrix-assisted laser desorption ionization–Fourier transform ion cyclotron resonance imaging (MALDI-FTICR) |
e-poster |
Atopic dermatitis |
||
JI. Silverberg |
Relationship between clinical severity assessments and patient-reported outcomes in atopic dermatitis |
e-poster |
C. Dias-Barbosa |
Assessment of sleep disturbances through patient self-report diary in atopic dermatitis |
e-poster |
S. Kwatra |
Economic burden of atopic dermatitis in the U.S. stratified by disease severity |
e-poster |
N. Lachman |
A moisturizer and a lotion rebalance skin microbiome in vitro |
e-poster |
S. Anjuwon |
A highly tolerated and efficient moisturizer dedicated for sensitive skins with atopic dermatitis (AD) |
e-poster |
C. Emesiani |
Comparison of an eczema soothing moisturizer versus itch relief moisturizing lotion on hydration and TEWL in patients with eczema-prone skin |
e-poster |
P. Lio |
The effect of an eczema soothing moisturizer on ceramide levels in patients with eczema-prone skin |
e-poster |
C. Emesiani |
Comparison of two OTC itch relief products after single application |
e-poster |
Rosacea |
||
M. Schaller |
Rosacea-tailored skincare routine integrated with ivermectin 1% cream and doxycycline 40mg or placebo provides benefits for patients with severe rosacea |
e-poster |
H. Baldwin |
Evolution of benzoyl peroxide: microencapsulated 5% cream to improve tolerability in papulopustular rosacea |
e-poster |
H. Baldwin |
Efficacy of subantibiotic doxycycline in rosacea: Focus on patient reported outcomes |
e-poster |
N. Bhatia |
E-BPO phase 3 trials: patient reported outcome |
e-poster |
N. Bhatia |
Novel technology for rosacea: microencapsulated benzoyl peroxide 5% for moderate to severe rosacea |
e-poster |
N. Bhatia |
Novel technology for rosacea: microencapsulated benzoyl peroxide 5% for long-term management of rosacea (E-BPO LTSS) |
e-poster |
Y. Nong |
Rosacea pathogenesis, microbiome, and skin barrier: a study of benzoyl peroxide cream, 5% |
e-poster |
JQ. Del Ros-so |
Subantibiotic dose doxycycline is effective in rosacea independent of patient weight and disease severity |
e-poster |
M. Schaller |
Ivermectin therapy for rosacea: app to quantify changes in erythema and skin texture |
e-poster |
M. Schaller |
Ivermectin: ocular rosacea |
e-poster |
M. Schaller |
Burning and stinging in rosacea treatments: a review of clinical evidence |
e-poster |
Acne |
||
H. Baldwin |
Re-formulating the old tretinoin: Unique microencapsulated tretinoin with microencapsulated benzoyl peroxide combination product for acne vulgaris |
e-poster |
JQ. Del Rosso |
Fixed-dose combination encapsulated benzoyl peroxide 3% plus encapsulated tretinoin 0.1% cream for treatment of acne vulgaris |
e-poster |
B. Dreno |
Trifarotene effects on ace-related gene expression |
e-poster |
JH. Lee |
Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean acne patients by randomized, double-blinded clinical trial |
e-poster |
A. Hebert |
Phase 3 pooled analysis of safety and efficacy of trifarotene 0.005% cream within adolescent population |
e-poster |
A. Layton |
Improving acne care recommendations from personalizing acne: Consensus of experts (PACE) |
e-poster |
JQ. Del Ros-so |
The DUAL study: efficacy, safety, and tolerability of topical trifarotene 50μg/g cream when used with enteric coated oral doxycycline 120mg in patients with severe acne vulgaris |
e-poster |
J. Sugarman |
Results from two Phase 1 safety studies of encapsulated benzoyl peroxide/tretinoin, 3%/0.1%: Release profile and potentials for skin irritation and sensitization |
e-poster |
J. Sugarman |
An evaluation of the phototoxic and photoallergic potential of microencapsulated benzoyl peroxide and microencapsulated tretinoin (E-BPO/T, 3%/0.1%) applied topically to the skin of healthy subjects |
e-poster |
J. Tan |
Trifarotene in context: exploring the acne burden in Latin America |
e-poster |
SM. Johnson |
A tailored skincare routine provides benefits to patients with severe acne vulgaris on topical trifarotene and oral doxycycline |
e-poster |
JQ. Del Rosso |
Efficacy, tolerability and acceptability of a 2.6% benzoyl peroxide acne cleanser specifically designed for sensitive skin |
e-poster |
JQ. Del Rosso |
Efficacy, tolerability, and cosmetic acceptability of an acne regimen specifically designed for sensitive skin |
e-poster |
Diabetes |
||
P. Lio |
Efficacy, tolerability, and acceptability of a balm formulated with dimethicone 1% in type II diabetes patients with dry, cracked skin |
e-poster |
D. Nussbaum |
A 10% urea moisturizer improves the signs and symptoms of foot xerosis in diabetic patients |
e-poster |
Skin tone |
||
JQ. Del Rosso |
Efficacy, tolerability, and consumer perception of a skincare regimen in patients with uneven skin tone |
e-poster |
Keratosis pilaris |
||
D. Nussbaum |
A moisturizing cream with 20% urea rapidly improves the signs & symptoms of keratosis pilaris |
e-poster |